Logo image of TCRX

TSCAN THERAPEUTICS INC (TCRX) Stock Fundamental Analysis

NASDAQ:TCRX - Nasdaq - US89854M1018 - Common Stock - Currency: USD

1.47  +0.04 (+2.8%)

After market: 1.445 -0.02 (-1.7%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TCRX. TCRX was compared to 555 industry peers in the Biotechnology industry. While TCRX seems to be doing ok healthwise, there are quite some concerns on its profitability. TCRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TCRX had negative earnings in the past year.
In the past year TCRX has reported a negative cash flow from operations.
TCRX had negative earnings in each of the past 5 years.
TCRX had a negative operating cash flow in each of the past 5 years.
TCRX Yearly Net Income VS EBIT VS OCF VS FCFTCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -39.52%, TCRX perfoms like the industry average, outperforming 56.76% of the companies in the same industry.
TCRX's Return On Equity of -62.55% is in line compared to the rest of the industry. TCRX outperforms 59.28% of its industry peers.
Industry RankSector Rank
ROA -39.52%
ROE -62.55%
ROIC N/A
ROA(3y)-33.47%
ROA(5y)-35.77%
ROE(3y)-59.56%
ROE(5y)-72.17%
ROIC(3y)N/A
ROIC(5y)N/A
TCRX Yearly ROA, ROE, ROICTCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TCRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRX Yearly Profit, Operating, Gross MarginsTCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

4

2. Health

2.1 Basic Checks

TCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TCRX has been increased compared to 1 year ago.
Compared to 5 years ago, TCRX has more shares outstanding
TCRX has a better debt/assets ratio than last year.
TCRX Yearly Shares OutstandingTCRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TCRX Yearly Total Debt VS Total AssetsTCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

TCRX has an Altman-Z score of -1.88. This is a bad value and indicates that TCRX is not financially healthy and even has some risk of bankruptcy.
TCRX has a Altman-Z score (-1.88) which is comparable to the rest of the industry.
TCRX has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TCRX (0.15) is worse than 68.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -1.88
ROIC/WACCN/A
WACC8.48%
TCRX Yearly LT Debt VS Equity VS FCFTCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 8.55 indicates that TCRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.55, TCRX is in the better half of the industry, outperforming 72.79% of the companies in the same industry.
TCRX has a Quick Ratio of 8.55. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.
TCRX's Quick ratio of 8.55 is fine compared to the rest of the industry. TCRX outperforms 72.79% of its industry peers.
Industry RankSector Rank
Current Ratio 8.55
Quick Ratio 8.55
TCRX Yearly Current Assets VS Current LiabilitesTCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

TCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.84%, which is quite good.
Looking at the last year, TCRX shows a very negative growth in Revenue. The Revenue has decreased by -70.16% in the last year.
The Revenue for TCRX have been decreasing by -34.76% on average. This is quite bad
EPS 1Y (TTM)14.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)-70.16%
Revenue growth 3Y-34.76%
Revenue growth 5YN/A
Sales Q2Q%283.57%

3.2 Future

TCRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.62% yearly.
Based on estimates for the next years, TCRX will show a very strong growth in Revenue. The Revenue will grow by 104.66% on average per year.
EPS Next Y0.62%
EPS Next 2Y-2.64%
EPS Next 3Y7.51%
EPS Next 5Y8.62%
Revenue Next Year106.13%
Revenue Next 2Y40.01%
Revenue Next 3Y155.08%
Revenue Next 5Y104.66%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TCRX Yearly Revenue VS EstimatesTCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
TCRX Yearly EPS VS EstimatesTCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TCRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRX Price Earnings VS Forward Price EarningsTCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRX Per share dataTCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.64%
EPS Next 3Y7.51%

More info and screens

0

5. Dividend

5.1 Amount

TCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TSCAN THERAPEUTICS INC

NASDAQ:TCRX (7/2/2025, 8:00:00 PM)

After market: 1.445 -0.02 (-1.7%)

1.47

+0.04 (+2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)N/A N/A
Inst Owners92.79%
Inst Owner Change-3.59%
Ins Owners0.26%
Ins Owner Change0%
Market Cap83.19M
Analysts84.29
Price Target8.67 (489.8%)
Short Float %4.36%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.71%
Min EPS beat(2)-7.46%
Max EPS beat(2)10.87%
EPS beat(4)3
Avg EPS beat(4)5.3%
Min EPS beat(4)-7.46%
Max EPS beat(4)14.81%
EPS beat(8)6
Avg EPS beat(8)13.93%
EPS beat(12)8
Avg EPS beat(12)8.76%
EPS beat(16)10
Avg EPS beat(16)-1.33%
Revenue beat(2)1
Avg Revenue beat(2)20.46%
Min Revenue beat(2)-51.71%
Max Revenue beat(2)92.64%
Revenue beat(4)1
Avg Revenue beat(4)-10.1%
Min Revenue beat(4)-78.27%
Max Revenue beat(4)92.64%
Revenue beat(8)2
Avg Revenue beat(8)-5.62%
Revenue beat(12)4
Avg Revenue beat(12)0.64%
Revenue beat(16)6
Avg Revenue beat(16)10.55%
PT rev (1m)-3.77%
PT rev (3m)-30%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.9%
EPS NY rev (1m)0%
EPS NY rev (3m)4.02%
Revenue NQ rev (1m)7.66%
Revenue NQ rev (3m)17.56%
Revenue NY rev (1m)53.5%
Revenue NY rev (3m)96.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.82
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-2.19
FCFYN/A
OCF(TTM)-2.11
OCFYN/A
SpS0.08
BVpS3.71
TBVpS3.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.52%
ROE -62.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.47%
ROA(5y)-35.77%
ROE(3y)-59.56%
ROE(5y)-72.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 131.71%
Cap/Sales 105.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.55
Quick Ratio 8.55
Altman-Z -1.88
F-Score4
WACC8.48%
ROIC/WACCN/A
Cap/Depr(3y)78.03%
Cap/Depr(5y)175.46%
Cap/Sales(3y)60.67%
Cap/Sales(5y)133.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y0.62%
EPS Next 2Y-2.64%
EPS Next 3Y7.51%
EPS Next 5Y8.62%
Revenue 1Y (TTM)-70.16%
Revenue growth 3Y-34.76%
Revenue growth 5YN/A
Sales Q2Q%283.57%
Revenue Next Year106.13%
Revenue Next 2Y40.01%
Revenue Next 3Y155.08%
Revenue Next 5Y104.66%
EBIT growth 1Y-36.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.53%
EBIT Next 3Y19.08%
EBIT Next 5YN/A
FCF growth 1Y-66.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.27%
OCF growth 3YN/A
OCF growth 5YN/A